CyberGene AB has acquired a patent for prenatal diagnostics of the Chromosome 22q11.2 deletion syndrome associated with congenital heart disease (CHD)
There are other available technologies for diagnosing chromosomal change in the q22.11.2 regionen. CyberGene's QF-PCR technology has a number of advantages such as; significantly lower cost, faster turn-around-time, and higher confidence in the results.
The test has been used by the innovators at a hospital in Palma, Mallorca on over 2 000 patients which in itself is a good indication of the value of the patent. CyberGene will continue to optimize the test and apply for regulatory approval according to CE-IVDR, and is assuming a timeline of 12 months before the product is market ready.
Read the full press release in Swedish here
Updates from CyberGene
Want to get started?
CyberGene supports your lab from start to routine diagnostics